An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens

Trial Profile

An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2017

At a glance

  • Drugs Avibactam/ceftazidime (Primary) ; Metronidazole
  • Indications Bacterial infections; Intra-abdominal infections; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms REPRISE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 Jan 2017 Results from complicated urinary tract infections (cUTI) patients published in an AstraZeneca Media Release
    • 30 Jan 2017 According to AstraZeneca media release, the U.S. Food and Drug Administration (FDA) has approved supplemental New Drug Application (sNDA) to update the label for AVYCAZ (ceftazidime and avibactam) to treat patients with complicated urinary tract infections (cUTI), including pyelonephritis, caused by designated susceptible Gram-negative microorganisms with clinical data from RECAPTURE and REPRISE trials.
    • 12 Nov 2016 Results published in the Antimicrobial Agents and Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top